These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients. Sato S; Kawashima H; Kashiwagi Y; Hoshika A Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640 [TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease. Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370 [TBL] [Abstract][Full Text] [Related]
6. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Kuo HC; Yang KD; Liang CD; Bong CN; Yu HR; Wang L; Wang CL Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314 [TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease. Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393 [TBL] [Abstract][Full Text] [Related]
8. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538 [TBL] [Abstract][Full Text] [Related]
9. Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C. Zhu YP; Shamie I; Lee JC; Nowell CJ; Peng W; Angulo S; Le LN; Liu Y; Miao H; Xiong H; Pena CJ; Moreno E; Griffis E; Labou SG; Franco A; Broderick L; Hoffman HM; Shimizu C; Lewis NE; Kanegaye JT; Tremoulet AH; Burns JC; Croker BA; J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464357 [TBL] [Abstract][Full Text] [Related]
10. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. Altznauer F; von Gunten S; Späth P; Simon HU J Allergy Clin Immunol; 2003 Dec; 112(6):1185-90. PubMed ID: 14657880 [TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous immunoglobulin on inhibiting peripheral blood lymphocyte apoptosis in acute Kawasaki disease. Yi QJ; Li CR; Yang XQ Acta Paediatr; 2001 Jun; 90(6):623-7. PubMed ID: 11440093 [TBL] [Abstract][Full Text] [Related]
12. Changes in Peripheral Blood Neutrophils, Lymphocytes and IL-10 in Children with Kawasaki Disease from Different Age Groups Undergoing Intravenous Immunoglobulin: A Retrospective Study. Zhang C; Zhang X; Shen J; Lu X; Zhang J; Chen S Mediators Inflamm; 2020; 2020():5213451. PubMed ID: 33293897 [TBL] [Abstract][Full Text] [Related]
13. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease]. Peng Q; Wu Q; Chen CH; Hong H; Zhang LY Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):208-10. PubMed ID: 16787593 [TBL] [Abstract][Full Text] [Related]
14. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. Fukunishi M; Kikkawa M; Hamana K; Onodera T; Matsuzaki K; Matsumoto Y; Hara J J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407 [TBL] [Abstract][Full Text] [Related]